Navigation Links
Menstrual Cramps May Be Helped by New Drug
Date:3/23/2010

If trials succeed, medication would block hormone that controls uterine contractions

TUESDAY, March 23 (HealthDay News) -- A new drug shows promise in treating severe menstrual cramps, researchers say.

The condition, called dysmenorrhea, affects 45 percent to 90 percent of women of child-bearing age and is the leading cause of school and job absenteeism among women in their teens and 20s, according to a news release from the American Chemical Society. Existing treatments, such as pain relievers, anti-inflammatory drugs and oral contraceptives, are ineffective in nearly one-third of women with moderate to severe dysmenorrhea, the news release noted.

Menstrual cramps are caused by contractions of the uterus. In dysmenorrhea, the uterus contracts with increased frequency.

The British pharmaceutical company Vantia Ltd. has developed an investigational pill, called VA111913, that's designed to block the hormone vasopressin, which plays a role in regulating contraction of the uterus.

Last year, a stage 1 clinical trial showed that VA111913 was safe. The drug is currently in Phase 2 clinical trials to evaluate how well it works to control pain in women with dysmenorrhea. The results of the studies, which are being conducted by Vantia, are expected later this year.

"We hope that the drug will provide a more effective treatment option for millions of women worldwide with this painful condition," Vantia's Andrzej R. Batt, said in the news release. "Dysmenorrhea not only diminishes the quality of life for millions of women, but also has a hidden, society-wide economic cost that involves an enormous number of days lost from work and school."

Details about the drug were to be presented Tuesday at the national meeting of the American Chemical Society in San Francisco.

More information

The University of Wisconsin has more about painful menstrual periods.



-- Robert Preidt



SOURCE: American Chemical Society, news release, March 23, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. How to Say Goodbye to Premenstrual Syndrome (PMS) With the Click of a Button - A New Way to Avoid PMS
2. Fish Oil Helped Stave Off Psychosis in Study Patients
3. Aggressive response helped Chilean hospital improve H1N1 influenza outcomes
4. Twenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis
5. Slouching Stars at the Oscars: Could the PostureNOW Posture Brace Have Helped Miley?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run ... This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed ... geared towards children of all ages; it is a non-competitive, non-timed event, which is ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/12/2017)... Del. (PRWEB) , ... October 12, 2017 , ... ... and advisory services for healthcare compliance program management, will showcase a range of ... National Association for Assisted Living (NCAL) Convention and Expo to be held October ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... 2017   Montrium , an industry leader ... the IQPC Trial Master Files & Inspection Readiness ... EastHORN Clinical Services has selected eTMF Connect ... management. EastHORN, a leading European contract research organization ... transparency to enable greater collaboration with sponsors, improve ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/22/2017)... AVACEN Medical (AVACEN) announced that its CE-Marked ... those with the widespread pain associated with fibromyalgia in ... Essex, England commented, "I had ... no sleep at all, tremendous pain, with every movement ... [the AVACEN 100] enough, how this has and is ...
Breaking Medicine Technology: